BR112016024352A2 - ?cepa de listeria recombinante, listeria recombinante, composição farmacêutica, e, métodos de induzir uma resposta imune contra um tumor ou um câncer em um indivíduo humano e de listeria? - Google Patents

?cepa de listeria recombinante, listeria recombinante, composição farmacêutica, e, métodos de induzir uma resposta imune contra um tumor ou um câncer em um indivíduo humano e de listeria?

Info

Publication number
BR112016024352A2
BR112016024352A2 BR112016024352-8A BR112016024352A BR112016024352A2 BR 112016024352 A2 BR112016024352 A2 BR 112016024352A2 BR 112016024352 A BR112016024352 A BR 112016024352A BR 112016024352 A2 BR112016024352 A2 BR 112016024352A2
Authority
BR
Brazil
Prior art keywords
listeria
recombinant listeria
tumor
inducing
cancer
Prior art date
Application number
BR112016024352-8A
Other languages
English (en)
Portuguese (pt)
Inventor
Wallecha Anu
Petit Robert
Original Assignee
Advaxis, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Advaxis, Inc. filed Critical Advaxis, Inc.
Publication of BR112016024352A2 publication Critical patent/BR112016024352A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/36—Adaptation or attenuation of cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/55—Fusion polypeptide containing a fusion with a toxin, e.g. diphteria toxin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20051—Methods of production or purification of viral material

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
BR112016024352-8A 2014-04-24 2015-04-14 ?cepa de listeria recombinante, listeria recombinante, composição farmacêutica, e, métodos de induzir uma resposta imune contra um tumor ou um câncer em um indivíduo humano e de listeria? BR112016024352A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461983732P 2014-04-24 2014-04-24
US61/983732 2014-04-24
PCT/US2015/025690 WO2015164121A1 (en) 2014-04-24 2015-04-14 Recombinant listeria vaccine strains and methods of producing the same

Publications (1)

Publication Number Publication Date
BR112016024352A2 true BR112016024352A2 (pt) 2018-01-23

Family

ID=54333010

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112016024352-8A BR112016024352A2 (pt) 2014-04-24 2015-04-14 ?cepa de listeria recombinante, listeria recombinante, composição farmacêutica, e, métodos de induzir uma resposta imune contra um tumor ou um câncer em um indivíduo humano e de listeria?

Country Status (15)

Country Link
US (2) US10258679B2 (OSRAM)
EP (1) EP3134510B1 (OSRAM)
JP (3) JP7009061B2 (OSRAM)
KR (2) KR102359691B1 (OSRAM)
CN (1) CN106459887A (OSRAM)
AU (1) AU2015250111A1 (OSRAM)
BR (1) BR112016024352A2 (OSRAM)
CA (1) CA2946716A1 (OSRAM)
IL (1) IL248483A0 (OSRAM)
MA (1) MA39849A (OSRAM)
MX (1) MX2016013985A (OSRAM)
RU (1) RU2016145464A (OSRAM)
SG (2) SG11201608820WA (OSRAM)
TW (2) TWI722858B (OSRAM)
WO (1) WO2015164121A1 (OSRAM)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9012141B2 (en) 2000-03-27 2015-04-21 Advaxis, Inc. Compositions and methods comprising KLK3 of FOLH1 antigen
WO2012125551A1 (en) 2011-03-11 2012-09-20 Advaxis Listeria-based adjuvants
SG11201405605VA (en) 2012-03-12 2014-10-30 Advaxis Inc SUPPRESSOR CELL FUNCTION INHIBITION FOLLOWING <i>LISTERIA</i> VACCINE TREATMENT
BR112016019057A2 (pt) 2014-02-18 2017-10-10 Advaxis Inc método de induzir uma resposta imune contra uma doença em um indivíduo
WO2015164121A1 (en) 2014-04-24 2015-10-29 Advaxis, Inc. Recombinant listeria vaccine strains and methods of producing the same
EP3207142A4 (en) * 2014-10-14 2018-07-04 The Trustees Of The University Of Pennsylvania Recombinant listeria vaccine strains and methods of using the same in cancer immunotherapy
MA41644A (fr) 2015-03-03 2018-01-09 Advaxis Inc Compositions à base de listeria comprenant un système d'expression de minigènes codant pour des peptides, et leurs procédés d'utilisation
US20170199961A1 (en) 2015-12-16 2017-07-13 Gritstone Oncology, Inc. Neoantigen Identification, Manufacture, and Use
CA3035591A1 (en) 2016-11-30 2018-06-07 Advaxis, Inc. Immunogenic compositions targeting recurrent cancer mutations and methods of use thereof
CN106978381A (zh) * 2017-03-23 2017-07-25 上海理工大学 prfA基因缺失单核细胞增生李斯特氏菌及制备方法
WO2019060115A1 (en) 2017-09-19 2019-03-28 Advaxis, Inc. COMPOSITIONS AND METHODS FOR LYOPHILIZATION OF BACTERIA OR LISTERIA STRAINS
CN118888004A (zh) 2017-10-10 2024-11-01 磨石生物公司 使用热点进行的新抗原鉴别
BR112020008512A2 (pt) 2017-10-31 2020-10-06 Pantarhei Bioscience B.V. métodos imunoterapêuticos para tratamento e/ou prevenção do câncer pulmonar
US11885815B2 (en) 2017-11-22 2024-01-30 Gritstone Bio, Inc. Reducing junction epitope presentation for neoantigens
SG11202008820WA (en) * 2018-03-09 2020-10-29 Advaxis Inc Compositions and methods for evaluating attenuation and infectivity of listeria strains
CN110408634B (zh) 2018-04-27 2021-08-03 苏州若泰医药科技有限公司 一种非整合李斯特菌疫苗及抗肿瘤免疫应答方法
US10973908B1 (en) 2020-05-14 2021-04-13 David Gordon Bermudes Expression of SARS-CoV-2 spike protein receptor binding domain in attenuated salmonella as a vaccine
WO2021259963A1 (en) 2020-06-23 2021-12-30 Pandora Endocrine Innovation B.V. Immunization against wnt4 for treatment and prophylaxis of breast cancer
WO2023066923A1 (en) 2021-10-19 2023-04-27 Rahman Nafis Male contraception
CN116218754B (zh) * 2023-04-10 2025-06-03 四川大学 一种提高绵羊李斯特菌膜囊泡产量的方法及应用
CN119060155B (zh) * 2024-11-07 2025-03-07 山东大学 一种蛋白在调节肠道稳态及抵抗致病菌感染中的应用

Family Cites Families (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5830702A (en) 1990-10-31 1998-11-03 The Trustees Of The University Of Pennsylvania Live, recombinant listeria monocytogenes and production of cytotoxic T-cell response
US20070264279A1 (en) * 1994-11-08 2007-11-15 Claudia Gravekamp Compositions and methods comprising a MAGE-b antigen
US8956621B2 (en) 1994-11-08 2015-02-17 The Trustees Of The University Of Pennsylvania Compositions and methods for treatment of cervical dysplasia
US8114414B2 (en) 1994-11-08 2012-02-14 The Trustees Of The University Of Pennsylvania Compositions and methods for treatment of cervical cancer
US7820180B2 (en) 2004-09-24 2010-10-26 The Trustees Of The University Of Pennsylvania Listeria-based and LLO-based vaccines
US8791237B2 (en) 1994-11-08 2014-07-29 The Trustees Of The University Of Pennsylvania Compositions and methods for treatment of non-hodgkins lymphoma
US6051237A (en) 1994-11-08 2000-04-18 The Trustees Of The University Of Pennsylvania Specific immunotherapy of cancer using a live recombinant bacterial vaccine vector
US7794729B2 (en) * 1994-11-08 2010-09-14 The Trustees Of The University Of Pennsylvania Methods and compositions for immunotherapy of cancer
US7662396B2 (en) * 2001-03-26 2010-02-16 The Trustees Of The University Of Pennsylvania Compositions and methods for enhancing the immunogenicity of antigens
US6099848A (en) 1997-11-18 2000-08-08 The Trustees Of The University Of Pennsylvania Immunogenic compositions comprising DAL/DAT double-mutant, auxotrophic, attenuated strains of Listeria and their methods of use
US9012141B2 (en) 2000-03-27 2015-04-21 Advaxis, Inc. Compositions and methods comprising KLK3 of FOLH1 antigen
US6855320B2 (en) 2000-03-29 2005-02-15 The Trustees Of The University Of Pennsylvania Fusion of non-hemolytic, truncated form of listeriolysin O to antigens to enhance immunogenicity
AU2001255196A1 (en) 2000-03-29 2001-10-08 The Trustees Of The University Of Pennsylvania Compositions and methods for enhancing immunogenicity of antigens
US8771702B2 (en) 2001-03-26 2014-07-08 The Trustees Of The University Of Pennsylvania Non-hemolytic LLO fusion proteins and methods of utilizing same
US7700344B2 (en) 2001-03-26 2010-04-20 The Trustees Of The University Of Pennsylvania Compositions and methods for enhancing the immunogenicity of antigens
JP2005527240A (ja) 2002-05-29 2005-09-15 ザ・レジェンツ・オブ・ザ・ユニバーシティ・オブ・カリフォルニア 弱毒リステリア種とこれを使用する方法
EP1594560A4 (en) 2003-01-09 2007-06-06 Univ Pennsylvania COMPOSITIONS, METHODS AND KITS FOR INCREASING THE IMMUNOGENICITY OF A BACTERIA VACCINE VECTOR
US7858097B2 (en) * 2004-08-13 2010-12-28 The Trustees Of The University Of Pennsylvania Antibiotic resistance free Listeria strains and methods for constructing and using same
JP5530065B2 (ja) 2004-08-13 2014-06-25 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア 抗生物質耐性欠失ワクチンの作成方法
US7855064B2 (en) 2004-08-13 2010-12-21 The Trustees Of The University Of Pennsylvania Antibiotic resistance free vaccines and methods for constructing and using same
CA2584130A1 (en) * 2004-10-18 2006-04-27 Medimmune, Inc. High cell density process for growth of listeria
US7935804B2 (en) 2006-03-01 2011-05-03 Aduro Biotech Engineered Listeria and methods of use thereof
DK2977456T3 (en) 2006-08-15 2018-01-22 Univ Pennsylvania Compositions comprising HMW-MAA and fragments thereof for the treatment of cancer
US8268326B2 (en) 2006-08-15 2012-09-18 The Trustees Of The University Of Pennsylvania Compositions comprising HMW-MAA and fragments thereof, and methods of use thereof
EP2147092A4 (en) 2007-04-16 2010-06-09 Univ Pennsylvania ANTIBIOTIC RESISTANCE-FREE LISTERIA TRIBES AND METHOD OF CONSTRUCTING AND USING THEREOF
US20110129499A1 (en) 2008-05-19 2011-06-02 Paulo Maciag Dual delivery system for heterologous antigens
US9084747B2 (en) 2009-11-11 2015-07-21 Advaxis, Inc. Compositions and methods for prevention of escape mutation in the treatment of HER2/NEU over-expressing tumors
KR20110027695A (ko) * 2008-05-19 2011-03-16 아두로 바이오테크 Ｐｒｆａ＊ 돌연변이 리스테리아를 포함하는 조성물 및 그것의 사용방법
US9650639B2 (en) 2008-05-19 2017-05-16 Advaxis, Inc. Dual delivery system for heterologous antigens
US20140234370A1 (en) 2009-11-11 2014-08-21 Advaxis, Inc. Compositions and methods for prevention of escape mutation in the treatment of her2/neu over-expressing tumors
US20150366955A9 (en) 2009-11-11 2015-12-24 Advaxis, Inc. Compositions and methods for prevention of escape mutation in the treatment of her2/neu over-expressing tumors
US20120135033A1 (en) 2008-05-19 2012-05-31 Anu Wallecha Multiple delivery system for heterologous antigens
US9017660B2 (en) 2009-11-11 2015-04-28 Advaxis, Inc. Compositions and methods for prevention of escape mutation in the treatment of Her2/neu over-expressing tumors
EP2331123A4 (en) * 2008-07-24 2012-11-07 Aduro Biotech COMPOSITIONS AND METHODS FOR TREATING HEPATITIS C
US8778329B2 (en) 2009-03-04 2014-07-15 The Trustees Of The University Of Pennsylvania Compositions comprising angiogenic factors and methods of use thereof
US10016617B2 (en) 2009-11-11 2018-07-10 The Trustees Of The University Of Pennsylvania Combination immuno therapy and radiotherapy for the treatment of Her-2-positive cancers
US20110223187A1 (en) 2010-02-15 2011-09-15 Vafa Shahabi Live listeria-based vaccines for central nervous system therapy
US20110305724A1 (en) 2010-04-19 2011-12-15 Yvonne Paterson Immunotherapeutic, anti-tumorigenic compositions and methods of use thereof
WO2012138377A2 (en) 2010-10-01 2012-10-11 Trustees Of The University Of Pennsylvania The use of listeria vaccine vectors to reverse vaccine unresponsiveness in parasitically infected individuals
PT2640842T (pt) 2010-11-17 2018-10-12 Providence Health & Services Oregon D/B/A Providence Portland Medical Center Métodos e composições para induzir uma resposta imune a egfrviii
WO2012125551A1 (en) * 2011-03-11 2012-09-20 Advaxis Listeria-based adjuvants
SG11201405605VA (en) 2012-03-12 2014-10-30 Advaxis Inc SUPPRESSOR CELL FUNCTION INHIBITION FOLLOWING <i>LISTERIA</i> VACCINE TREATMENT
BR112016019057A2 (pt) 2014-02-18 2017-10-10 Advaxis Inc método de induzir uma resposta imune contra uma doença em um indivíduo
CA2940646A1 (en) 2014-02-25 2015-09-03 Advaxis, Inc. Compositions and methods for the treatment of her2/neu over-expressing tumors
RU2016138601A (ru) 2014-03-05 2018-04-05 Адваксис, Инк. Способы и композиции для повышения соотношения эффекторных т-клеток к регуляторным т-клеткам
WO2015164121A1 (en) 2014-04-24 2015-10-29 Advaxis, Inc. Recombinant listeria vaccine strains and methods of producing the same
AU2015253737A1 (en) 2014-05-02 2016-12-22 The Trustees Of The University Of Pennsylvania Combination immuno therapy and radiotherapy for the treatment of Her-2-positive cancers
MX2017000836A (es) 2014-07-18 2017-11-17 Advaxis Inc Composiciones inmunogenicas basadas en listeria para inducir respuestas antitumorales.
CN106999561A (zh) 2014-07-18 2017-08-01 阿德瓦希斯股份有限公司 用于治疗前列腺癌的pd‑1拮抗剂和基于李斯特菌的疫苗的组合
CN107073094A (zh) 2014-07-18 2017-08-18 阿德瓦希斯公司 表达异源性抗原融合蛋白的重组李斯特菌菌株及其使用方法
WO2016011320A1 (en) 2014-07-18 2016-01-21 Advaxis, Inc. Bivalent listeria-based delivery system of heterologous antigens
EP3207142A4 (en) 2014-10-14 2018-07-04 The Trustees Of The University Of Pennsylvania Recombinant listeria vaccine strains and methods of using the same in cancer immunotherapy
MA41217A (fr) 2014-12-19 2017-10-24 Advaxis Inc Polythérapies ayant des souches de listeria recombinées
WO2016126878A2 (en) 2015-02-03 2016-08-11 The Trustees Of The University Of Pennsylvania Listeria-based immunomodulation
US20160220652A1 (en) 2015-02-03 2016-08-04 Advaxis, Inc. Methods of using recombinant listeria vaccine strains in disease immunotherapy
WO2016126876A2 (en) 2015-02-03 2016-08-11 Advaxis, Inc. Listeria-based adjuvants
MA41644A (fr) 2015-03-03 2018-01-09 Advaxis Inc Compositions à base de listeria comprenant un système d'expression de minigènes codant pour des peptides, et leurs procédés d'utilisation
WO2016154412A2 (en) 2015-03-26 2016-09-29 The Trustees Of The University Of Pennsylvania Combination of a pd-1 antagonist and a listeria based vaccine for treating pancreatic cancer
WO2016183361A1 (en) 2015-05-13 2016-11-17 Advaxis, Inc. Immunogenic listeria-based compositions comprising truncated acta-antigen fusions and methods of use thereof
KR20180026670A (ko) 2015-05-26 2018-03-13 어드박시스, 인크. 맞춤형 전달 벡터-기반의 면역 요법 및 이의 용도
KR20180027501A (ko) 2015-06-24 2018-03-14 어드박시스, 인크. 맞춤형 전달 벡터-기반 면역 요법을 위한 제조 장치 및 공정
HK1258860A1 (zh) 2015-09-15 2019-11-22 Advaxis, Inc. 含有重组李斯特氏菌株的免疫治疗制剂的制作方法
EP3350332A1 (en) 2015-09-15 2018-07-25 Advaxis, Inc. Listeria-based immunogenic compositions and methods of use thereof in cancer prevention and treatment
AU2016324170A1 (en) 2015-09-17 2018-04-12 Advaxis, Inc. Recombinant Listeria vaccine strains and methods of using the same in cancer immunotherapy
TW201722444A (zh) 2015-10-14 2017-07-01 艾法西斯公司 重組李斯特菌疫苗菌株及在癌症免疫治療中使用該菌株之方法
WO2017085691A1 (en) 2015-11-20 2017-05-26 Advaxis, Inc. Manufacturing device and method of an immunotherapeutic formulation comprising a recombinant listeria strain
AU2016369580A1 (en) 2015-12-16 2018-07-12 Advaxis, Inc. Listeria-based immunotherapy and methods of use thereof
MA47398A (fr) 2016-01-27 2019-12-11 Advaxis Inc Immunothérapie à base de vecteurs d'administration personnalisés et utilisations associées
CN109641945A (zh) 2016-07-05 2019-04-16 阿德瓦希斯公司 包含维尔姆斯瘤蛋白抗原的基于李斯特菌的免疫原性组合物及其使用方法
MA46721A (fr) 2016-11-07 2019-09-11 Advaxis Inc Combinaison d'un vaccin à base de listeria avec des anticorps anti-ctla-4 ou anti-cd137
CA3035591A1 (en) 2016-11-30 2018-06-07 Advaxis, Inc. Immunogenic compositions targeting recurrent cancer mutations and methods of use thereof
WO2018102585A1 (en) 2016-11-30 2018-06-07 Advaxis, Inc. Personalized immunotherapy in combination with immunotherapy targeting recurrent cancer mutations
TW201833323A (zh) 2017-01-05 2018-09-16 美商艾法西斯公司 重組李斯特菌屬疫苗菌株及在癌症免疫治療中使用該菌株之方法

Also Published As

Publication number Publication date
TWI692525B (zh) 2020-05-01
KR102359691B1 (ko) 2022-02-10
AU2015250111A1 (en) 2016-12-08
TWI722858B (zh) 2021-03-21
WO2015164121A1 (en) 2015-10-29
IL248483A0 (en) 2016-12-29
KR102491332B1 (ko) 2023-01-27
JP2022105768A (ja) 2022-07-14
RU2016145464A (ru) 2018-05-24
MA39849A (fr) 2017-03-01
JP7009061B2 (ja) 2022-01-25
JP2017513502A (ja) 2017-06-01
US10258679B2 (en) 2019-04-16
JP2020099352A (ja) 2020-07-02
CN106459887A (zh) 2017-02-22
EP3134510A4 (en) 2018-04-25
EP3134510B1 (en) 2023-11-01
US20190240303A1 (en) 2019-08-08
CA2946716A1 (en) 2015-10-29
TW202041671A (zh) 2020-11-16
US20170042996A1 (en) 2017-02-16
KR20160145627A (ko) 2016-12-20
SG10202011841WA (en) 2021-01-28
JP7300041B2 (ja) 2023-06-28
EP3134510A1 (en) 2017-03-01
SG11201608820WA (en) 2016-11-29
KR20220021021A (ko) 2022-02-21
TW201546276A (zh) 2015-12-16
MX2016013985A (es) 2017-01-11

Similar Documents

Publication Publication Date Title
BR112016024352A2 (pt) ?cepa de listeria recombinante, listeria recombinante, composição farmacêutica, e, métodos de induzir uma resposta imune contra um tumor ou um câncer em um indivíduo humano e de listeria?
MX2018004598A (es) Cepas vacunales recombinantes de listeria y métodos para usar las mismas en la inmunoterapia contra el cáncer.
SG10201903349YA (en) Recombinant listeria vaccine strains and methods of using the same in cancer immunotherapy
EP4421094A3 (en) Targeted therapeutic agents and uses thereof
BR112016020364A2 (pt) métodos para suscitar uma resposta de uma célula t antitumoral em um indivíduo tendo um tumor ou câncer e para aumentar a razão de células t efetoras sobre células t reguladoras no baço de um indivíduo
PH12019501414A1 (en) Amino acid compositions and methods for the treatment of liver diseases
CO2018004564A2 (es) Genes de ataxia de friedreich modificados y vectores para terapia génica
MX2022005291A (es) Vacunas para el tratamiento y prevencion del cancer.
PH12019501010A1 (en) Arginase inhibitor combination therapies
NI201800052A (es) Anticuerpos que neutraliza el virus respiratorio sincitial humano
MD4733B1 (ro) Anticorpi anti-TIGIT
MX2019007352A (es) Composiciones de aminoacidos y metodos para el tratamiento de enfermedades y transtornos musculares.
MX2021006017A (es) Polipeptidos de folistatina y sus usos.
MX2017004838A (es) Composiciones de interleucina-15 y usos de estas.
IN2014CN04187A (OSRAM)
MX2015009963A (es) Metodos y composición farmacéutica para el tratamiento y la prevención de cardiomiopatía debido a falta de energía.
MY173162A (en) Immune balance regulator
ZA202204223B (en) Vaccination with mica/b alpha 3 domain for the treatment of cancer
CY1119957T1 (el) Θεραπεια νοσηματων με τη χρηση ανοχογονου φαρμακευτικου παρασκευασματος
MX2018015110A (es) Arn modificado que codifica polipeptidos de vegf-a. formulaciones y usos relacionados con los mismos.
MY193807A (en) T-cell receptor and uses thereof
MX2020002585A (es) Inhibidor de hdac combinado con un modulador del punto de control inmunitario para la terapia contra el cancer.
MX2019003970A (es) Péptidos de arginasa inmunogénicos.
MX2019006446A (es) Métodos para inducir tolerancia inmunológica a factores de coagulación.
MY190102A (en) Tolerogenic dna vaccine

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements